SCHEMBL30413601

SCHEMBL30413601

CCOC(=O)c1cnc(Cl)nc1NN(C)C(=O)OC(C)(C)C

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SYK P43405 4/20 0.57
▸ STK17B O94768 1/20 0.41
▸ STK17A Q9UEE5 1/20 0.41
▸ ALDH1A1 P00352 4/20 0.40
▸ NFKB1 P19838 6/20 0.39
▸ NFKB2 Q00653 5/20 0.39
▸ RELA Q04206 5/20 0.39
▸ FOS P01100 4/20 0.39
▸ JUN P05412 4/20 0.39
▸ ATF1 P18846 1/20 0.39
▸ MAPT P10636 3/20 0.39
▸ HPGD P15428 1/20 0.39
▸ MAPK1 P28482 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ SMN1; SMN2 Q16637 4/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ LMNA P02545 1/20 0.38
▸ NPC1 O15118 2/20 0.38
▸ RAB9A P51151 2/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25227768 1.00 SYK (0.57) SYKSTK17BSTK17AALDH1A1NFKB1
SCHEMBL25031184 0.86 ALDH1A1 (0.57) SYKALDH1A1NFKB1NFKB2RELA
SCHEMBL23625406 0.77 SYK (0.50) SYKALDH1A1NFKB1NFKB2RELA
SCHEMBL14810384 0.77 KDM4E (0.57) SYKALDH1A1NFKB1NFKB2RELA
SCHEMBL23620399 0.77 SYK (0.54) SYKALDH1A1NFKB1NFKB2RELA
SCHEMBL2523948 0.76 SYK (0.53) SYKALDH1A1NFKB1NFKB2RELA
SCHEMBL24851336 0.75 SYK (0.48) SYKALDH1A1NFKB1NFKB2RELA
SCHEMBL22401330 0.75 STK17B (0.51) SYKSTK17BSTK17AALDH1A1NFKB1
SCHEMBL12942870 0.75 SYK (0.64) SYKSTK17BSTK17AALDH1A1MAPT
SCHEMBL30504113 0.75 STK17B (0.51) SYKSTK17BSTK17AALDH1A1NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250066348-A1 SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF INSILICO MEDICINE IP LIMITED (HK) 2025-02-27 — — US disclosed
EP-4430049-A1 SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF Insilico Medicine IP Limited (HK) 2024-09-18 — — EP disclosed
WO-2023083285-A1 SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF INSILICO MEDICINE IP LIMITED (CN) 2023-05-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250066348-A1 SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF USP1, USP2, USP28 SYK 3491/4885STK17B 1219/4885STK17A 1307/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback